CN104936600B - 孕甾-4-烯-20-炔-3-酮用于治疗抑郁症的用途 - Google Patents

孕甾-4-烯-20-炔-3-酮用于治疗抑郁症的用途 Download PDF

Info

Publication number
CN104936600B
CN104936600B CN201380062351.9A CN201380062351A CN104936600B CN 104936600 B CN104936600 B CN 104936600B CN 201380062351 A CN201380062351 A CN 201380062351A CN 104936600 B CN104936600 B CN 104936600B
Authority
CN
China
Prior art keywords
application according
alkynes
alkene
ketone
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380062351.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN104936600A (zh
Inventor
路易斯·蒙蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pherin Corp
Original Assignee
Pherin Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pherin Corp filed Critical Pherin Corp
Publication of CN104936600A publication Critical patent/CN104936600A/zh
Application granted granted Critical
Publication of CN104936600B publication Critical patent/CN104936600B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201380062351.9A 2012-12-28 2013-12-19 孕甾-4-烯-20-炔-3-酮用于治疗抑郁症的用途 Active CN104936600B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261747167P 2012-12-28 2012-12-28
US61/747,167 2012-12-28
PCT/US2013/076497 WO2014105620A1 (en) 2012-12-28 2013-12-19 Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders

Publications (2)

Publication Number Publication Date
CN104936600A CN104936600A (zh) 2015-09-23
CN104936600B true CN104936600B (zh) 2018-08-03

Family

ID=49950051

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380062351.9A Active CN104936600B (zh) 2012-12-28 2013-12-19 孕甾-4-烯-20-炔-3-酮用于治疗抑郁症的用途

Country Status (11)

Country Link
US (1) US10322138B2 (enExample)
EP (1) EP2938346B1 (enExample)
JP (1) JP6283689B2 (enExample)
KR (1) KR102209475B1 (enExample)
CN (1) CN104936600B (enExample)
AU (1) AU2013371025B2 (enExample)
CA (1) CA2894686C (enExample)
DK (1) DK2938346T3 (enExample)
ES (1) ES2625778T3 (enExample)
MX (1) MX369774B (enExample)
WO (1) WO2014105620A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
ES2972282T3 (es) * 2019-04-15 2024-06-12 Vistagen Therapeutics Inc Tratamiento de la migraña
WO2024254005A1 (en) 2023-06-04 2024-12-12 Vistagen Therapeutics, Inc. 1,3,5(10),16-estratetraen-3-yl acetate for use in improving psychomotor or cognitive performance
US20250312356A1 (en) * 2024-04-08 2025-10-09 Vistagen Therapeutics, Inc. Treatment of dysmenorrhea

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028904A1 (en) * 1993-06-15 1994-12-22 Pherin Corporation Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
CN1173181A (zh) * 1994-08-04 1998-02-11 弗伦有限公司 作为在下丘脑功能中发生改变的神经化学引发剂的孕甾烷和胆甾烷
US6057439A (en) * 1994-08-04 2000-05-02 Pherin Corporation Steroids as neurochemical stimulators of the VNO to alleviate symptoms of PMS and anxiety

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5303703A (en) 1991-10-03 1994-04-19 Pherin Corporation Combined neuroepithelial sample delivery electrode device and methods of using same
US6066627A (en) 1994-08-04 2000-05-23 Pherin Corporation Steroids as neurochemical initiators of change in human blood levels of LH
US5563131A (en) * 1994-08-04 1996-10-08 Pherin Corporation Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
US6117860A (en) 1994-08-04 2000-09-12 Pherin Pharmaceuticals, Inc. Steroids as neurochemical stimulators of the VNO to treat paroxistic tachycardia
US6331534B1 (en) 1994-08-04 2001-12-18 Pherin Pharmaceuticals, Inc. Steroids as neurochemical stimulators of the VNO to alleviate pain
JP4450435B2 (ja) * 1996-07-23 2010-04-14 フィーリン・ファーマシューティカルズ・インコーポレイテッド Ｐｍｓおよび不安の症状を緩和する、ｖｎｏにおける神経化学刺激物質としてのステロイド
US20020123138A1 (en) * 2000-11-30 2002-09-05 Jian Zhang Human VNO receptor (R1)
US20030045514A1 (en) 2001-05-03 2003-03-06 Louis Monti 17-Methyleneandrostan-3alpha-ol analogs as CRH inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028904A1 (en) * 1993-06-15 1994-12-22 Pherin Corporation Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
CN1173181A (zh) * 1994-08-04 1998-02-11 弗伦有限公司 作为在下丘脑功能中发生改变的神经化学引发剂的孕甾烷和胆甾烷
US6057439A (en) * 1994-08-04 2000-05-02 Pherin Corporation Steroids as neurochemical stimulators of the VNO to alleviate symptoms of PMS and anxiety

Also Published As

Publication number Publication date
CA2894686A1 (en) 2014-07-03
EP2938346A1 (en) 2015-11-04
KR20150100884A (ko) 2015-09-02
MX369774B (es) 2019-11-21
WO2014105620A1 (en) 2014-07-03
CN104936600A (zh) 2015-09-23
EP2938346B1 (en) 2017-04-05
MX2015008454A (es) 2016-05-16
CA2894686C (en) 2021-05-04
US20140187524A1 (en) 2014-07-03
HK1210421A1 (en) 2016-04-22
JP2016504361A (ja) 2016-02-12
AU2013371025B2 (en) 2018-01-18
DK2938346T3 (en) 2017-06-12
AU2013371025A1 (en) 2015-07-09
KR102209475B1 (ko) 2021-01-28
ES2625778T3 (es) 2017-07-20
JP6283689B2 (ja) 2018-02-21
US10322138B2 (en) 2019-06-18

Similar Documents

Publication Publication Date Title
CH680983A5 (enExample)
CN104936600B (zh) 孕甾-4-烯-20-炔-3-酮用于治疗抑郁症的用途
ES2273374T3 (es) Esteroides como estimuladores neuroquimicos del ovn para aliviar los sintomas de pms.
CN102056484B (zh) 用于热潮红的类固醇治疗
HK1210421B (en) Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders
US8722652B2 (en) Acute treatment of social phobia
AU2020259269B2 (en) Treatment of migraine
US20250312356A1 (en) Treatment of dysmenorrhea
CN101272683A (zh) 治疗与焦虑有关疾病的方法
HK40068177A (en) Treatment of migraine
HK40068177B (en) Treatment of migraine
WO2024254005A1 (en) 1,3,5(10),16-estratetraen-3-yl acetate for use in improving psychomotor or cognitive performance
Wharton et al. The use of transdermal 17β-estradiol in the treatment of AlzheimerTs disease

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant